Article thumbnail

Integrin Imaging to Evaluate Treatment Response

By Matthew Morrison and Alan Cuthbertson


Despite the recent development of various radiolabelled RGD peptides for imaging the αvβ3 integrin receptor, relatively little attention has been focused on the ability of these radiotracers to monitor changes in tumour vascularity following treatment with anti-tumour therapies. Here we describe the favourable in vivo kinetics and tumour targeting properties of several novel radiolabeled RGD containing peptides that have the ability to monitor tumour vascularity non-invasively in a variety of preclinical tumor models. These tracers may reveal important information when assessing the impact of anti-tumour therapies, in particular those that predominantly target tumour blood vessels. Consequently, these radiolabelled RGD targeting agents represent a useful approach to quantify tumor vasculature, and when used alone or in combination with additional functional imaging modalities, should enhance our mechanistic understanding of how novel therapeutic strategies impact upon tumors

Topics: Review
Publisher: Ivyspring International Publisher
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1995). A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins.
  2. (1997). Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol.
  3. Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis?
  4. (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov.
  5. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.
  6. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro Oncol.
  7. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us.
  8. Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
  9. Eskens FA. Vascular disrupting agents in clinical development.
  10. (2007). Evaluation of a 99mTc-labeled cyclic RGD tetramer for noninvasive imaging integrin αvβ3-positive breast cancer. Bioconjug Chem.
  11. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
  12. Imaging of tumor angiogenesis: current approaches and future prospects. Curr Pharm Des.
  13. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.
  14. (1992). Integrins: versatility, modulation, and signaling in cell adhesion.
  15. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
  16. Micro-PET imaging of αvβ3-integrin expression with 18F-labeled dimeric RGD peptide. Mol Imaging.
  17. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Bioorg Med Chem Lett.
  18. (2009). Noninvasive imaging of αvβ3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res.
  19. (2005). Noninvasive visualization of the activated αvβ3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med.
  20. (1999). Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm.
  21. (2008). Patterns of αvβ3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET.
  22. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res.
  23. Platelet-derived growth factor in human glioma.
  24. Radiotracer-based strategies to image angiogenesis.
  25. Report from the society for biological therapy and vascular biology faculty of the NCI workshop on angiogenesis monitoring.
  26. (1994). Taxol (paclitaxel): mechanisms of action. Ann Oncol.
  27. The RGD radioligand [18F]AH111585: A novel probe for imaging αvβ3 and αvβ5 receptor levels by positron emission tomography in breast cancer patients.
  28. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.
  29. (1997). The αvβ3 integrin "vitronectin receptor".
  30. (1999). Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res.
  31. Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy.
  32. (2006). Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program.
  33. (2000). ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res.